ETIDRONIC ACID

US Previously Marketed

Details

Stereochemistry	ACHIRAL
Molecular Formula	C2H8O7P2
Molecular Weight	206.0282
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(O)(P(O)(O)=O)P(O)(O)=O

InChI

InChIKey=DBVJJBKOTRCVKF-UHFFFAOYSA-N

InChI=1S/C2H8O7P2/c1-2(3,10(4,5)6)11(7,8)9/h3H,1H3,(H2,4,5,6)(H2,7,8,9)

HIDE SMILES / InChI

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017831s058lbl.pdf |

Etidronate is a salt of etidronic acid (brand name Didronel, also known as EHDP) a diphosphonate, which is indicated for the treatment of symptomatic Paget’s disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury. Didronel is not approved for the treatment of osteoporosis. This drugs acts primarily on bone. It can inhibit the formation, growth, and dissolution of hydroxyapatite crystals and their amorphous precursors by chemisorption to calcium phosphate surfaces. Inhibition of crystal resorption occurs at lower doses than are required to inhibit crystal growth. Both effects increase as the dose increases. Preclinical studies indicate etidronate disodium does not cross the blood-brain barrier. Didronel is not metabolized. The amount of drug absorbed after an oral dose is approximately 3 percent. Bisphosphonates, when attached to bone tissue, are absorbed by osteoclasts, the bone cells that breaks down bone tissue. Although the mechanism of action of non-nitrogenous bisphosphonates has not been fully elucidated, available data suggest that they bind strongly to hydroxyapatite crystals in the bone matrix, preferentially at the sites of increased bone turnover and inhibit the formation and dissolution of the crystals. Other actions may include direct inhibition of mature osteoclast function, promotion of osteoclast apoptosis, and interference with osteoblast-mediated osteoclast activation. Etidronic acid may promote osteoclast apoptosis by competing with adenosine triphosphate (ATP) in the cellular energy metabolism. The osteoclast initiates apoptosis and dies, leading to an overall decrease in the breakdown of bone.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Hydroxyapatite 20 Target ID: CHEMBL2363055 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16046206	Antagonist 2737
ATP 10 Target ID: CHEMBL2366048 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21111853	Inhibitor 8146

Conditions

Condition	Modality	Targets	Highest Phase	Product
Paget’s disease of bone 12 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017831s058lbl.pdf	Primary		Approved 8307	DIDRONEL Approved Use Didronel is indicated for the treatment of symptomatic Paget’s disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury. Didronel is not approved for the treatment of osteoporosis. Paget’s Disease: Didronel is indicated for the treatment of symptomatic Paget's disease of bone. Didronel therapy usually arrests or significantly impedes the disease process as evidenced by: --Symptomatic relief, including decreased pain and/or increased mobility (experienced by 3 out of 5 patients). --Reductions in serum alkaline phosphatase and urinary hydroxyproline levels (30 percent or more in 4 out of 5 patients). --Histomorphometry showing reduced numbers of osteoclasts and osteoblasts, and more lamellar bone formation. Bone scans showing reduced radionuclide uptake at pagetic lesions. In addition, reductions in pagetically elevated cardiac output and skin temperature have been observed in some patients. In many patients, the disease process will be suppressed for a period of at least 1 year following cessation of therapy. The upper limit of this period has not been determined. The effects of the Didronel treatment in patients with asymptomatic Paget's disease have not been studied. However, Didronel treatment of such patients may be warranted if extensive involvement threatens irreversible neurologic damage, major joints, or major weight-bearing bones. Heterotopic Ossification: Didronel is indicated in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury. Didronel reduces the incidence of clinically important heterotopic bone by about two-thirds. Among those patients who form heterotopic bone, Didronel retards the progression of immature lesions and reduces the severity by at least half. Follow-up data (at least 9 months posttherapy) suggest these benefits persist. In total hip replacement patients, Didronel does not promote loosening of the prosthesis or impede trochanteric reattachment. In spinal cord injury patients, Didronel does not inhibit fracture healing or stabilization of the spine. Launch Date 2.4192E11
Heterotopic ossification 7 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017831s058lbl.pdf	Preventing		Approved 8307	DIDRONEL Approved Use Didronel is indicated for the treatment of symptomatic Paget’s disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury. Didronel is not approved for the treatment of osteoporosis. Paget’s Disease: Didronel is indicated for the treatment of symptomatic Paget's disease of bone. Didronel therapy usually arrests or significantly impedes the disease process as evidenced by: --Symptomatic relief, including decreased pain and/or increased mobility (experienced by 3 out of 5 patients). --Reductions in serum alkaline phosphatase and urinary hydroxyproline levels (30 percent or more in 4 out of 5 patients). --Histomorphometry showing reduced numbers of osteoclasts and osteoblasts, and more lamellar bone formation. Bone scans showing reduced radionuclide uptake at pagetic lesions. In addition, reductions in pagetically elevated cardiac output and skin temperature have been observed in some patients. In many patients, the disease process will be suppressed for a period of at least 1 year following cessation of therapy. The upper limit of this period has not been determined. The effects of the Didronel treatment in patients with asymptomatic Paget's disease have not been studied. However, Didronel treatment of such patients may be warranted if extensive involvement threatens irreversible neurologic damage, major joints, or major weight-bearing bones. Heterotopic Ossification: Didronel is indicated in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury. Didronel reduces the incidence of clinically important heterotopic bone by about two-thirds. Among those patients who form heterotopic bone, Didronel retards the progression of immature lesions and reduces the severity by at least half. Follow-up data (at least 9 months posttherapy) suggest these benefits persist. In total hip replacement patients, Didronel does not promote loosening of the prosthesis or impede trochanteric reattachment. In spinal cord injury patients, Didronel does not inhibit fracture healing or stabilization of the spine. Launch Date 2.4192E11

PubMed

Title	Date	PubMed
Possibility of "distraction arthrogenesis": first report in rabbit model.	2001	11793183
Effect of menatetrenone on bone mineral density and incidence of vertebral fractures in postmenopausal women with osteoporosis: a comparison with the effect of etidronate.	2001	11793169
Etidronate for treating and preventing postmenopausal osteoporosis.	2001	11687195
Effect of intermittent cyclical treatment with etidronate disodium (HEBP) and calcium plus alphacalcidol in postmenopausal osteoporosis.	2001	11484098
Analgesic effect of etidronate on degenerative joint disease.	2001	11448018
Guidelines for treatment of osteoporosis in men.	2001 Aug	11681154
186Re-1,4,8,11-tetraaza cyclotetradecyl-1,4,8,11-tetramethylene phosphonic acid: a novel agent for possible use in metastatic bone-pain palliation.	2001 Aug	11518653
Subcutaneous fat necrosis of the newborn following hypothermia and complicated by pain and hypercalcaemia.	2001 Aug	11488718
Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis.	2001 Dec	11728926
[Therapy of osteoporosis. Risk factors alone are not an indication].	2001 Dec 6	11813710
[Fluorides and bisphosphonates in the treatment of osteoporosis].	2001 Jul	11515184
Role of bisphosphonates and calcitonin in the prevention and treatment of osteoporosis.	2001 Jul	11485341
The in-vitro porcine adhesion model is not predictive of the esophageal transit of risedronate tablets in humans.	2001 Jul 17	11427349
Clinical effect of etidronate on alveolar pyorrhoea associated with chronic marginal periodontitis: report of four cases.	2001 Jul-Aug	11675910
Prevalence and determinants of osteoporosis drug prescription among patients with high exposure to glucocorticoid drugs.	2001 Jun	11439733
(31)P NMR of apicomplexans and the effects of risedronate on Cryptosporidium parvum growth.	2001 Jun 15	11396947
186Re-etidronate. Efficacy of palliative radionuclide therapy for painful bone metastases.	2001 Mar	11456380
Prevention and treatment of osteoporosis.	2001 Mar-Apr	11333463
Incadronate and etidronate accelerate phosphate-primed mineralization of MC4 cells via ERK1/2-Cbfa1 signaling pathway in a Ras-independent manner: further involvement of mevalonate-pathway blockade for incadronate.	2001 May	11430477
Management of male osteoporosis.	2001 May	11394626
Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption.	2001 May	11348880
Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women.	2001 May	11344179
The role of combination treatment for osteoporosis.	2001 May	11344178
Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro.	2001 May	11344045
[Bisphosphonates in osteoporosis. Significantly reduces risk of fracture].	2001 May 3	11393183
The effect of risedronate on the risk of hip fracture in elderly women.	2001 May 31	11386283
[Alternatives to hormonal treatment for the prevention of postmenopausal osteoporosis: the bisphosphonates].	2001 Nov	11770280
Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage.	2001 Nov	11768198
Role of alendronate and risedronate in preventing and treating osteoporosis.	2001 Nov	11718433
Rhenium-188 HEDP to treat painful bone metastases.	2001 Nov	11595844
Conventional treatment of hypercalcemia of malignancy.	2001 Nov 15	11757206
Advances in the biology and treatment of myeloma bone disease.	2001 Nov 15	11757204
A method to assess the proportion of treatment effect explained by a surrogate endpoint.	2001 Nov 15	11746311
[Economic aspects of osteoporosis therapy. What does a prevented fracture cost?].	2001 Nov 22	11791359
Risedronate treatment and extended fracture protection in postmenopausal women.	2001 Nov-Dec	11791630
Treatment of osteoporosis in men with fluoride alone or in combination with bisphosphonates.	2001 Oct	11730262
Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy.	2001 Oct	11730260
Alendronate for the treatment of osteoporosis in men.	2001 Oct	11730259
Maintenance of cancellous bone in ovariectomized, human parathyroid hormone [hPTH(1-84)]-treated rats by estrogen, risedronate, or reduced hPTH.	2001 Oct	11595618
Painful multifocal arthritis: therapy with rhenium 186 hydroxyethylidenediphosphonate ((186)Re HEDP) after failed treatment with medication--initial results of a prospective study.	2001 Oct	11568349
[Osteoporosis. Fracture as alarm signal].	2001 Oct 11	11721665
The diagnosis of Paget's disease.	2001 Sep	11584586
Effects of high-dose etidronate treatment on microdamage accumulation and biomechanical properties in beagle bone before occurrence of spontaneous fractures.	2001 Sep	11557372
Alendronate does not interfere with 99mTc-methylene diphosphonate bone scanning.	2001 Sep	11535725
Pharmacologic therapy for the treatment and prevention of osteoporosis.	2001 Sep	11532658
Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates.	2001 Sep 1	11520816
Zinc diphosphonates templated by organic amines: syntheses and characterizations of [NH3(CH2)2NH3]Zn(hedpH2)22H2O and [NH3(CH2)nNH3(CH2)nNH3]Zn2(hedpH)22H2O (n=4,5,6) (hedp=1-hydroxyethylidenediphophonate).	2001 Sep 10	11531453
Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase.	2001 Sep 7	11435429
Positive effect of etidronate therapy is maintained after drug is terminated in patients using corticosteroids.	2001 Winter	11748341
Discovery of a high molecular weight complex of calcium, phosphate, fetuin, and matrix gamma-carboxyglutamic acid protein in the serum of etidronate-treated rats.	2002 Feb 8	11724771

Patents

Sample Use Guides

In Vivo Use Guide

should be taken as a single, oral dose. Paget’s Disease: Initial Treatment Regimens: 5 to 10 mg/kg/day, not to exceed 6 months, or 11 to 20 mg/kg/day, not to exceed 3 months. The recommended initial dose is 5 mg/kg/day for a period not to exceed 6 months. Doses above 10 mg/kg/day should be reserved for when 1) lower doses are ineffective or 2) there is an overriding need to suppress rapid bone turnover (especially when irreversible neurologic damage is possible) or reduce elevated cardiac output. Doses in excess of 20 mg/kg/day are not recommended.

Route of Administration: Oral

In Vitro Use Guide

In vitro cytotoxicity of etidronic acid to MCF-7 cells was estimated on the basis of clonogenicity assays, while cell cycle effects were determined by using flow cytometry. A 24-hour treatment with etidronic acid (10 mM) with or without strontium chloride was cytototoxic to MCF-7cells. Etidronic acid (1, 10 mM) caused a decrease in the S-phase population and an increase in the G2/M population. Treatment of MCF-7 human breast cancer cells with etidronic acid (10 mM) for six hours caused mutations in exons 6 and 8 of the p53 gene in MCF-7 cells.

Name

Type

Language

ETIDRONIC ACID

Official Name

English

ETIDRONATE

Common Name

English

ETIDRONIC ACID [INCI]

Common Name

English

M05BA01

Code

English

(1-Hydroxyethylidene)diphosphonic acid

Systematic Name

English

HYDROXYETHYLIDENE-1,1-DIPHOSPHONIC ACID

Systematic Name

English

etidronic acid [INN]

Common Name

English

ETIDRONIC ACID [HSDB]

Common Name

English

(1-HYDROXY-ETHYLIDENE)DIPHOSPHONIC ACID

Systematic Name

English

NSC-227995

Code

English

PHOSPHONIC ACID, (1-HYDROXYETHYLIDENE)BIS-

Common Name

English

ETIDRONIC ACID [USAN]

Common Name

English

PHOSPHONIC ACID, P,P'-(1-HYDROXYETHYLIDENE)BIS-

Systematic Name

English

ETIDRONATE [VANDF]

Common Name

English

Etidronic acid [WHO-DD]

Common Name

English

1-HYDROXYETHANE-1,1-BISPHOSPHONIC ACID

Systematic Name

English

ETIDRONIC ACID [MART.]

Common Name

English

OEDP

Common Name

English

ETIDRONIC ACID [MI]

Common Name

English

Classification Tree Code System Code

Food Contact Sustance Notif, (FCN No.)

FCN NO. 1096

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

Food Contact Sustance Notif, (FCN No.)

FCN NO. 699

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

Food Contact Sustance Notif, (FCN No.)

FCN NO. 1144

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

Food Contact Sustance Notif, (FCN No.)

FCN NO. 691

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

Food Contact Sustance Notif, (FCN No.)

FCN NO. 1247

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

WHO-ATC

M05BB01

Created by admin on Sun Dec 18 21:00:58 UTC 2022 , Edited by admin on Sun Dec 18 21:00:58 UTC 2022

WHO-VATC

QM05BA01

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

LIVERTOX

386

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

NDF-RT

N0000175579

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

Food Contact Sustance Notif, (FCN No.)

FCN NO. 561

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

Food Contact Sustance Notif, (FCN No.)

FCN NO. 1081

Created by admin on Sun Dec 18 21:00:58 UTC 2022 , Edited by admin on Sun Dec 18 21:00:58 UTC 2022

Food Contact Sustance Notif, (FCN No.)

FCN NO. 1082

Created by admin on Sun Dec 18 21:00:58 UTC 2022 , Edited by admin on Sun Dec 18 21:00:58 UTC 2022

NCI_THESAURUS

C443

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

Food Contact Sustance Notif, (FCN No.)

FCN NO. 1094

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

Food Contact Sustance Notif, (FCN No.)

FCN NO. 625

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

Food Contact Sustance Notif, (FCN No.)

FCN NO. 951

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

Food Contact Sustance Notif, (FCN No.)

FCN NO. 724

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

Food Contact Sustance Notif, (FCN No.)

FCN NO. 670

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

Food Contact Sustance Notif, (FCN No.)

FCN NO. 908

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

Food Contact Sustance Notif, (FCN No.)

FCN NO. 1089

Created by admin on Sun Dec 18 21:00:58 UTC 2022 , Edited by admin on Sun Dec 18 21:00:58 UTC 2022

Food Contact Sustance Notif, (FCN No.)

FCN NO. 641

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

Food Contact Sustance Notif, (FCN No.)

FCN NO. 993

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

Food Contact Sustance Notif, (FCN No.)

FCN NO. 1236

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

WHO-ATC

M05BA01

Created by admin on Sun Dec 18 21:00:58 UTC 2022 , Edited by admin on Sun Dec 18 21:00:58 UTC 2022

Food Contact Sustance Notif, (FCN No.)

FCN NO. 921

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

Food Contact Sustance Notif, (FCN No.)

FCN NO. 1035

Created by admin on Sun Dec 18 21:00:58 UTC 2022 , Edited by admin on Sun Dec 18 21:00:58 UTC 2022

Food Contact Sustance Notif, (FCN No.)

FCN NO. 1132

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

Food Contact Sustance Notif, (FCN No.)

FCN NO. 801

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

Food Contact Sustance Notif, (FCN No.)

FCN NO. 323

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

Food Contact Sustance Notif, (FCN No.)

FCN NO. 1093

Created by admin on Sun Dec 18 21:00:58 UTC 2022 , Edited by admin on Sun Dec 18 21:00:58 UTC 2022

Food Contact Sustance Notif, (FCN No.)

FCN NO. 728

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

Food Contact Sustance Notif, (FCN No.)

FCN NO. 447

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

WHO-VATC

QM05BB01

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

Food Contact Sustance Notif, (FCN No.)

FCN NO. 880

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

Food Contact Sustance Notif, (FCN No.)

FCN NO. 887

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

NCI_THESAURUS

C67439

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

Food Contact Sustance Notif, (FCN No.)

FCN NO. 140

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

NDF-RT

N0000007707

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

Food Contact Sustance Notif, (FCN No.)

FCN NO. 911

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

Code System Code Type Description

ECHA (EC/EINECS)

220-552-8

Created by admin on Sun Dec 18 21:00:58 UTC 2022 , Edited by admin on Sun Dec 18 21:00:58 UTC 2022

PRIMARY

NSC

227995

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

PRIMARY

PUBCHEM

3305

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

PRIMARY

INN

2758

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

PRIMARY

FDA UNII

M2F465ROXU

Created by admin on Sun Dec 18 21:00:58 UTC 2022 , Edited by admin on Sun Dec 18 21:00:58 UTC 2022

PRIMARY

MERCK INDEX

M5182

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

PRIMARY

Merck Index

DRUG BANK

DB01077

Created by admin on Sun Dec 18 21:00:58 UTC 2022 , Edited by admin on Sun Dec 18 21:00:58 UTC 2022

PRIMARY

MESH

D012968

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

PRIMARY

LACTMED

Etidronate

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

PRIMARY

EPA CompTox

DTXSID6023028

Created by admin on Sun Dec 18 21:00:58 UTC 2022 , Edited by admin on Sun Dec 18 21:00:58 UTC 2022

PRIMARY

DRUG CENTRAL

1098

Created by admin on Sun Dec 18 21:00:58 UTC 2022 , Edited by admin on Sun Dec 18 21:00:58 UTC 2022

PRIMARY

HSDB

5898

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

PRIMARY

DAILYMED

M2F465ROXU

Created by admin on Sun Dec 18 21:00:58 UTC 2022 , Edited by admin on Sun Dec 18 21:00:58 UTC 2022

PRIMARY

CHEBI

4907

Created by admin on Sun Dec 18 21:00:58 UTC 2022 , Edited by admin on Sun Dec 18 21:00:58 UTC 2022

PRIMARY

IUPHAR

7184

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

PRIMARY

NCI_THESAURUS

C1332

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

PRIMARY

RXCUI

1356715

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

PRIMARY

WIKIPEDIA

Etidronic acid

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

PRIMARY

ChEMBL

CHEMBL871

Created by admin on Sun Dec 18 21:00:58 UTC 2022 , Edited by admin on Sun Dec 18 21:00:58 UTC 2022

PRIMARY

CAS

2809-21-4

Created by admin on Sun Dec 18 21:00:58 UTC 2022 , Edited by admin on Sun Dec 18 21:00:58 UTC 2022

PRIMARY

RXCUI

42682

Created by admin on Sun Dec 18 21:00:59 UTC 2022 , Edited by admin on Sun Dec 18 21:00:59 UTC 2022

ALTERNATIVE

EVMPD

SUB07299MIG

Created by admin on Sun Dec 18 21:00:58 UTC 2022 , Edited by admin on Sun Dec 18 21:00:58 UTC 2022

PRIMARY

ACTIVE MOIETY


					M2F465ROXU

ETIDRONIC ACID

SALT/SOLVATE (PARENT)


					HWB1KVT9Z5

MONOPOTASSIUM ETIDRONATE

SALT/SOLVATE (PARENT)


					FF53VF097S

ETIDRONATE PENTAPOTASSIUM MONOHYDRATE

SALT/SOLVATE (PARENT)


					DV7W6W681S

RHENIUM RE-186 ETIDRONATE

SALT/SOLVATE (PARENT)


					CVI36ET72E

TETRAPOTASSIUM ETIDRONATE

SALT/SOLVATE (PARENT)


					8SS5TWI75G

DIPOTASSIUM ETIDRONATE

SALT/SOLVATE (PARENT)


					M16PXG993G

ETIDRONATE DISODIUM

SALT/SOLVATE (PARENT)


					K49SH0Z84H

DICALCIUM ETIDRONATE

SALT/SOLVATE (PARENT)

TECHNETIUM TC-99M ETIDRONATE KIT

SALT/SOLVATE (PARENT)


					43663WR0HQ

ETIDRONATE PENTAPOTASSIUM

SALT/SOLVATE (PARENT)


					6Z2J8X3Q6U

TRISODIUM ETIDRONATE

SALT/SOLVATE (PARENT)


					2R11JA60QK

ETIDRONATE PENTASODIUM

SALT/SOLVATE (PARENT)


					CZZ9T1T1X4

ETIDRONATE TETRASODIUM

SALT/SOLVATE (PARENT)


					BCZ8ETH6PD

MONOSODIUM ETIDRONATE

SALT/SOLVATE (PARENT)


					13W7DMI45X

TECHNETIUM TC-99M ETIDRONATE

SALT/SOLVATE (PARENT)


					XWW2JNQ850

RHENIUM RE-188 ETIDRONATE

SALT/SOLVATE (PARENT)


					RB325UD2VG

TRIPOTASSIUM ETIDRONATE

Details

SMILES

InChI

DescriptionSources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017831s058lbl.pdf |

CNS Activity

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017831s058lbl.pdf |